Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus capecitabine versus placebo plus capecitabine in advanced HER2-negative breast cancer
2010-018501-10Phase 3Completed
- Sponsor
- Bayer
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sorafenib and capecitabine in breast cancer (2 arms), sponsored by Bayer. Primary endpoint: Progression-free survival. Started Nov 2010; status: completed.
02
Drugs
sorafenibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-018501-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018501-10.